ReDS™ Lite, a Next-Gen Non-Invasive Pulmonary Fluid Monitoring Device, Receives NMPA Approval in China
MitrAssist Lifesciences
Cardiovascular Innovative Medical Device R&D Manufacturer
Good News
Warm Congratulations
New Generation Non-Invasive Lung Water Measurement Device ReDS™ Lite
Approved for marketing in China!
Lighter weight
ReDS™ Lite weighs less than 2kg, and its lightweight design makes the device easy to carry and operate, especially suitable for clinical environments that require frequent movement. The detachable sensor allows for better positioning and is more adaptable to the body types of Chinese people.
Faster Measurement
A rapid measurement time of 25 seconds makes the diagnostic process faster, saving precious waiting time for patients while improving the responsiveness of medical services. It helps doctors quickly obtain data and make timely decisions.
Lower selling price
A lower selling price makes ReDS™ Lite competitive in terms of cost-effectiveness, enabling it to be more widely applied in various medical institutions, especially in budget-limited healthcare units or grassroots hospitals, thereby helping more patients benefit from this advanced heart failure management technology.
The launch event for the new ReDS™ Lite product will be held on February 15, 2025. More product information will be revealed at the event. We look forward to sharing this innovative moment with you.
Expert Commentary
Member of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference
Vice Chairman of the Central Committee of Jiusan Society
Academician of the Chinese Academy of Sciences
Director of Cardiology, Zhongshan Hospital, Fudan University
With the development of Chinese society and the aging of the population structure,Heart Failure in ChinaThe total population of patients is still increasing year by year. For a long time, there has been a lack of effective heart failure patient management devices in clinical practice. The ReDS™ Non-Invasive Lung Water Measurement Device can provide strong support for the long-term management of heart failure patients in hospitals by monitoring the absolute value of the patient's lung water content.
Member of the Heart Failure Association of the European Society of Cardiology (ESC-HFA)
World-renowned heart failure expert
Investigator in Over 100 Heart Failure Clinical Trials
United States, Ohio State University Wexner Medical Center
ReDS™, as a non-invasive, rapid, and precise quantitative device for measuring lung water content in patients, has the potential to transform the current difficult long-term management of heart failure patients and the lack of effective monitoring technology.
Stefan Anker
Former ESC-HFA President
ESC_Heart Failure Founding Editor-in-Chief
Germany, Charité Campus, Cardiology Department
The development and launch of ReDS™ bring new opportunities for the management of heart failure patients. How to assist hospitals in advancing the implementation at various stages of heart failure patient management, and guide doctors to use ReDS™ values to improve and standardize treatment plans for heart failure patients, will be an important task for the ReDS™ Scientific Committee.
Dan Bensimhon
Renowned Cardiologist in the United States
Cone_Health Medical Group
Congestion symptoms are the main reason for heart failure readmission. Even for well-trained medical staff, it is difficult to accurately assess congestion symptoms in heart failure patients. ReDS™ provides non-invasive, precise, and absolute measurements at almost any point of care. They are highly operable and can be incorporated into diagnostic/treatment protocols. Several ongoing studies demonstrate the use of ReDS™ and its improvement on patient outcomes.
MitrAssist Lifesciences, established in 2017, is a globally leading innovative platform-based medical device enterprise in the cardiovascular field. Its products cover major areas such as structural heart, heart failure, and coronary artery, with a rich product pipeline. The company owns 156 authorized PCT patents globally. It is a representative enterprise of "future materials" in Shanghai's future industry. Currently, it has research and development centers in China, Israel, and Germany, and has established operations in the United States.An independent sales team has been established, and a mature dealer system has been set up in multiple overseas countries.
The founding team of the group company consists of senior professionals who have深耕多年 in the medical industry, possessing disruptive technological innovation capabilities and卓越的国际化视野. Since its establishment, MitrAssist Lifesciences has always adhered to the mission of "MitrAssist Lifesciences, with heart as the lamp, utilizing global technology to heal hearts worldwide," striving to achieve the universal accessibility of cardiovascular medical diagnosis and treatment as its strategic mission. Continuously innovating and aiming to achieve "excellence where others have competence, and uniqueness where others do not."
On July 6, 2022, the world's first polymer valve Polymer TAVR product, SIKELIA™, independently developed by MitrAssist Lifesciences, was successfully implanted in the world's first clinical case by a team led by Academician Ge Junbo at Zhongshan Hospital, Fudan University, Shanghai. This marks the entry of interventional treatment for valvular heart disease into a new polymer era. Currently, this product has completed one-year postoperative follow-up for patients in the FIM clinical trial, with the longest follow-up reaching 27 months. It was also selected for the "World’s Largest Cardiovascular Events" list at this year’s TCT conference. The project also won the highest award, the "Outstanding Award," in the 2022 National Disruptive Technology Innovation Competition organized by the Ministry of Science and Technology. MitrAssist Lifesciences independently developed China’s first transapical mitral valve interventional replacement product.MitraFix® has entered the special review for innovative medical devices by the National Medical Products Administration. This product is not only safe and reliable but also easy to use, convenient for promotion, and requires only full ultrasound guidance throughout the surgery. ReDS™ Pro, a non-invasive heart failure management device from MitrAssist Lifesciences, has been approved for marketing in China after being launched in the US, Europe, India, and Japan. The ReDS device is currently the world's only non-invasive heart failure management device that meets the 5A principle. In the coronary field, MitrAssist Lifesciences’ product “Paclitaxel Drug-CoatedCoronary Balloon Dilatation Catheter"——XunNiao® has been approved for marketing in China, as the first approved product of its kind domestically using 4th generation paclitaxel drug coating technology.